This legislation is poised to have significant ramifications for the Medicare reimbursement framework associated with clinical diagnostic laboratory services. It proposes to enhance the accuracy of payment rates through a more representative sampling of data, rather than requiring detailed reporting from every laboratory. This shift is expected to benefit both laboratories—by reducing administrative burdens—and patients, by potentially ensuring they receive more accurate pricing for diagnostic services covered by Medicare.
Summary
House Bill 2377, titled the 'Saving Access to Laboratory Services Act,' is aimed at amending Title XVIII of the Social Security Act to improve the accuracy of Medicare payments for clinical diagnostic laboratory services. It seeks to address longstanding concerns around the administrative burdens associated with data collection and reporting currently imposed on laboratories. By implementing statistical sampling for broadly utilized laboratory tests, the bill intends to streamline the reporting process, making it easier for laboratories to comply with Medicare requirements.
Contention
While there is broad support for enhancing payment accuracy and reducing unnecessary burdens, some stakeholders may express concerns regarding the reliance on sampling as opposed to comprehensive data collection. Critics might argue that statistical sampling could overlook smaller laboratories or less commonly performed tests, potentially affecting their reimbursement rates or leading to disparities in service access across different provider types. Additionally, the bill includes limitations on payment increases, which could affect how laboratories adapt to changing costs and inflation in the healthcare market.
Requires hospital laboratories and bio-analytical or clinical laboratories to offer test for hepatitis C to certain individuals; authorizes certain laboratories to perform rapid tests for hepatitis C.
Finn Sawyer Access to Cancer Testing Act This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer. Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.